Autoimmune diseases (AIDs) are associated with strong female preponderance and often present before or during the reproductive years; consequently, pregnancy and breastfeeding are topics of major interest for these patients. AIDs show different responses to pregnancy: some ameliorate, while others remain unchanged, and several AIDs aggravate. The response of the AIDs to the hormonal and immunological alterations of pregnancy reflects the different pathophysiology of each disease. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are associated with multiple autoantibodies, multiorgan involvement, more aggressive therapy, and increased impact on pregnancy outcome. For the management of pregnancy in patients with SLE and/or APS, it is important to individuate the correct risk profile for each woman and timing for treatment. The optimal timing for starting or modulating treatment is at preconception assessment to influence the placentation. In this chapter, we discuss the management of pregnancy in patients with AIDs.

De Carolis, S., Moresi, S., Rizzo, F., Monteleone, G., Tabacco, S., Salvi, S., Garufi, C., Lanzone, A., Autoimmunity in obstetrics and autoimmune diseases in pregnancy, <<BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY>>, 2019; 60 (60): 66-76. [doi:10.1016/j.bpobgyn.2019.03.003] [http://hdl.handle.net/10807/151192]

Autoimmunity in obstetrics and autoimmune diseases in pregnancy

De Carolis, Sara;Rizzo, Francesca;Salvi, Silvia;Lanzone, Antonio
2019

Abstract

Autoimmune diseases (AIDs) are associated with strong female preponderance and often present before or during the reproductive years; consequently, pregnancy and breastfeeding are topics of major interest for these patients. AIDs show different responses to pregnancy: some ameliorate, while others remain unchanged, and several AIDs aggravate. The response of the AIDs to the hormonal and immunological alterations of pregnancy reflects the different pathophysiology of each disease. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are associated with multiple autoantibodies, multiorgan involvement, more aggressive therapy, and increased impact on pregnancy outcome. For the management of pregnancy in patients with SLE and/or APS, it is important to individuate the correct risk profile for each woman and timing for treatment. The optimal timing for starting or modulating treatment is at preconception assessment to influence the placentation. In this chapter, we discuss the management of pregnancy in patients with AIDs.
2019
Inglese
De Carolis, S., Moresi, S., Rizzo, F., Monteleone, G., Tabacco, S., Salvi, S., Garufi, C., Lanzone, A., Autoimmunity in obstetrics and autoimmune diseases in pregnancy, <<BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY>>, 2019; 60 (60): 66-76. [doi:10.1016/j.bpobgyn.2019.03.003] [http://hdl.handle.net/10807/151192]
File in questo prodotto:
File Dimensione Formato  
151192.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 303.14 kB
Formato Unknown
303.14 kB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/151192
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact